Patents Represented by Attorney Arnold & Porter LLP

Find this attorney in the Justia Lawyer Directory

  • Compositions and methods for the treatment of tumor of hematopoietic origin
    Patent number: 7754441
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: November 28, 2006
    Date of Patent: July 13, 2010
    Assignee: Genentech, Inc.
    Inventors: Frederic J. de Sauvage, Dan L. Eaton, Allen J. Ebens, Jr., Andrew Polson, Victoria Smith, Suzie J. Scales
  • Antibodies to IL-17 polypeptides and therapeutic uses thereof
    Patent number: 7749500
    Abstract: The present invention is directed to novel polypeptides having sequence identity with IL-17 and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders.
    Type: Grant
    Filed: August 7, 2008
    Date of Patent: July 6, 2010
    Assignee: Genentech, Inc.
    Inventors: Jian Chen, Ellen Filvaroff, Audrey Goddard, Austin Gurney, Hanzhong Li, William I. Wood
  • T cell receptor CDR3 sequences associated with multiple sclerosis and compositions comprising same
    Patent number: 7744893
    Abstract: The present invention relates generally to the field of treating and monitoring multiple sclerosis by utilizing T-cell receptors peptides. In particular, nucleic acids and peptide sequences of T-cell receptors found in a population of MS patients are provided, along with compositions comprising such TCR peptides for use in, e.g., vaccines.
    Type: Grant
    Filed: June 5, 2003
    Date of Patent: June 29, 2010
    Assignees: Baylor College of Medicine, Opexa Pharmaceuticals, Inc.
    Inventor: Jingwu Z. Zhang
  • Inhibitors of angiopoietin-like 4 protein, combinations, and their use
    Patent number: 7740846
    Abstract: Modulators of angiopoietin-like 4 protein are provided along with methods for their use in the treatment of diseases and pathological conditions. Combinations of ANGPTL4 antagonists and other therapeutics, e.g., anti-cancer agents, and methods of their use in the treatment of mammals susceptible to or diagnosed with cancer, or with relapse tumor growth or relapse cancer cell growth are also provided.
    Type: Grant
    Filed: July 19, 2005
    Date of Patent: June 22, 2010
    Assignee: Genentech, Inc.
    Inventors: Hanspeter Gerber, Napoleone Ferrara, Xiao Huan Liang
  • APO-2 ligand/trail formulations
    Patent number: 7741285
    Abstract: The present invention relates generally to Apo2L/TRAIL purification involving crystallization.
    Type: Grant
    Filed: May 24, 2005
    Date of Patent: June 22, 2010
    Assignee: Genentech, Inc.
    Inventors: Heather Flores, Tanya P. Lin, Timothy C. Matthews, Roger Pai, Zahra Shahrokh
  • Use of A33 antigens and JAM-IT
    Patent number: 7741056
    Abstract: The present invention relates to compositions and methods of treating and diagnosing disorders characterized the by the presence of antigens associated with inflammatory diseases and/or cancer.
    Type: Grant
    Filed: March 15, 2007
    Date of Patent: June 22, 2010
    Assignee: Genentech, Inc.
    Inventors: Avi Ashkenazi, Sherman Fong, Audrey Goddard, Austin L. Gurney, Mary A. Napier, Daniel Tumas, Menno Van Lookeren, William I. Wood
  • Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling
    Patent number: 7737259
    Abstract: Compositions and methods are provided for the diagnosis and treatment of inflammation and autoimmune disorders, such as psoriasis. Compositions and methods for modulating IL-23 or IL-22 signaling are provided.
    Type: Grant
    Filed: November 30, 2006
    Date of Patent: June 15, 2010
    Assignee: Genentech, Inc.
    Inventors: Yvonne M. Chen, Anan Chuntharapai, Dimitry Danilenko, Wenjun Ouyang, Susan Sa, Patricia Valdez, Terence Wong, Jianfeng Wu, Yan Zheng
  • Serpentine transmembrane antigens expressed in human cancers and uses thereof
    Patent number: 7727533
    Abstract: Described is a family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigen of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family is STEAP-1, which appears to be a type IIIa membrane protein. STEAP-1 is a 339 amino acid protein. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STEAP-1 is highly over-expressed in certain other human cancers.
    Type: Grant
    Filed: May 28, 2004
    Date of Patent: June 1, 2010
    Assignee: Genentech, Inc.
    Inventors: Daniel E. Afar, Rene S. Hubert, Arthur B. Raitano, Douglas Saffran, Steven Chappell Mitchell
  • Monoclonal antibodies to secreted and transmembrane polypeptides
    Patent number: 7723488
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: July 21, 2004
    Date of Patent: May 25, 2010
    Assignee: Genentech, Inc.
    Inventors: Luc Desnoyers, Ellen Filvaroff, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
  • Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
    Patent number: 7718397
    Abstract: The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Grant
    Filed: June 10, 2003
    Date of Patent: May 18, 2010
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul Godowski, J. Christopher Grimaldi, Austin Gurney, Colin Watanabe, William I. Wood
  • Transformation of sp. with using embryogenic callus cultures
    Patent number: 7714191
    Abstract: The present invention relates to a method for transforming Allium species with a heterologous gene using Agrobacterium.
    Type: Grant
    Filed: June 5, 2006
    Date of Patent: May 11, 2010
    Assignee: Seminis Vegetable Seeds, Inc.
    Inventor: John Reynolds
  • Multifunctional protease inhibitors and their use in treatment of disease
    Patent number: 7709446
    Abstract: Fusion proteins of protease inhibitors are provided, in particular fusion proteins of alpha 1-antitrypsin (AAT) and a second protease inhibitor, such as secretory leukocyte protease inhibitor (SLPI) or tissue inhibitor of metalloproteases (TIMP). Polynucleotides encoding the fusion proteins, vectors comprising such polynucleotides, and host cells containing such vectors are also provided. Methods of making the fusion proteins of the invention are also provide, as well as methods of using the fusion proteins, for example to inhibit protease activity in a biological sample or in the treatment of an individual suffering from, or at risk for, a disease or disorder involving unwanted protease activity.
    Type: Grant
    Filed: July 20, 2007
    Date of Patent: May 4, 2010
    Assignee: Arrive Pharmaceuticals, Inc.
    Inventors: Philip J. Barr, Helen L. Gibson, Philip A. Pemberton
  • Transgenic plants containing altered levels of sterol compounds and tocopherols
    Patent number: 7709666
    Abstract: Provided are recombinant constructs comprising DNA sequences encoding enzymes effective in altering the biosynthesis and accumulation of sterol compounds and tocopherols in transgenic plants. Also provided are methods of using such constructs to produce transgenic plants, seeds of which contain elevated levels of sitostanol and/or sitostanol esters, and ?-tocopherol, as well as reduced levels of campesterol and campestanol and their corresponding esters. These seeds also contain the novel sterol brassicastanol. Oil obtained from seeds of such transgenic plants is also provided. This oil can be used to prepare food and pharmaceutical compositions effective in lowering the level of low density lipoprotein cholesterol in blood serum. In addition, novel DNA sequences encoding plant steroid 5?-reductases are also disclosed.
    Type: Grant
    Filed: January 16, 2004
    Date of Patent: May 4, 2010
    Assignee: Monsanto Technology LLC
    Inventors: Mylavarapu Venkatramesh, David R. Corbin, B. Ganesh Bhat, Sekhar S. Boddupalli, Robert J. Grebenok, Ganesh M. Kishore, Kathryn D. Lardizabal, Michael W. Lassner, Shaukat H. Rangwala, Balasulojini Karunanandaa
  • Nucleotide and amino acid sequences from and uses thereof
    Patent number: 7696340
    Abstract: The invention provides isolated nucleotide sequences from Xenorhabdus nematophila species Xs86068, and, in particular, nucleotide sequences that encode insect inhibitory proteins, the insecticidal proteins, and compositions that comprise one or more of the insecticidal proteins for use in controlling insect infestation.
    Type: Grant
    Filed: November 30, 2007
    Date of Patent: April 13, 2010
    Assignee: Monsanto Technology LLC
    Inventors: Barry S. Goldman, Karina Krasomil-Osterfeld, Thomas M. Malvar, John W. Pitkin, Steven C. Slater, Wei Wu, Jiamin Zeng
  • Protein formulation
    Patent number: 7682609
    Abstract: A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.
    Type: Grant
    Filed: May 26, 2006
    Date of Patent: March 23, 2010
    Assignee: Genentech, Inc.
    Inventors: James Andya, Jeffrey L. Cleland, Chung C. Hsu, Xanthe M. Lam, David E. Overcashier, Steven J. Shire, Janet Yu-Feng Yang, Sylvia Sau-Yan Wu
  • Low pungency long day onion
    Patent number: 7671255
    Abstract: The present invention includes long-day onion plants comprising bulbs having low pungency and methods for obtaining such onions. The present invention also provides reagents and materials that can be used in the methods for obtaining such onions.
    Type: Grant
    Filed: July 14, 2006
    Date of Patent: March 2, 2010
    Assignee: Seminis Vegetable Seeds, Inc.
    Inventor: Scott Hendricks
  • Mammalian cell culture process
    Patent number: 7666416
    Abstract: The present invention relates to novel process for the preparation of glycoproteins by mammalian-cell culture wherein the sialic acid content of the glycoprotein' produced is controlled over a broad range of values by manipulating the cell culture environment. The invention provides for processes in which the sialic acid content of the glycoprotein is modified by changes in cell culture parameters which affect cell specific productivity. Preferred embodiments of the invention include cell culture processes in the osmolality of the cell culture is controlled as well as the concentration of a transcription enhancer during the production phase of the cell culture. The invention further provides for novel preparations of-soluble type 1 tumor necrosis factor immunoglobulin G1 and their uses in the treatment of inflammatory or immune related disorders.
    Type: Grant
    Filed: February 2, 2007
    Date of Patent: February 23, 2010
    Assignee: Genentech, Inc.
    Inventors: Tina Etcheverry, Thomas Ryll
  • ErbB4 receptor-specific neuregulin related ligands and uses therefor
    Patent number: 7662585
    Abstract: The invention concerns a novel neuregulin related ligand (NRG3) including fragments and variants thereof, as new members of the neuregulin family of compounds. The invention also concerns methods and means for producing NRG3. The native polypeptides of the invention are characterized by containing an extracellular domain including an EGF-like domain, a transmembrane domain and a cytoplasmic domain. Isolated nucleotide sequences encoding such polypeptides, expression vectors containing the nucleotide sequences, recombinant host cells transformed with the vectors, and methods for the recombinant production for the novel NRG3s are also within the scope of the invention.
    Type: Grant
    Filed: September 17, 2004
    Date of Patent: February 16, 2010
    Assignee: Genentech, Inc.
    Inventors: Paul J. Godowski, Melanie Rose Mark, Dong-Xiao Zhang
  • ErbB2 and ErbB3 chimeric heteromultimer adhesins
    Patent number: 7659368
    Abstract: Novel chimeric heteromultimer adhesins that bind the ligand of natural heteromultimeric receptors and uses therefor are disclosed. The chimeric molecules of the heteromultimer adhesins comprise an extracellular domain of a heteromultimeric receptor monomer and a multimerization domain for the stable interaction of the chimeric molecules in the adhesin. Specifically disclosed are heteromultimeric adhesins comprising the extracellular domains of ErbB2 and ErbB3 or ErbB2 and ErbB4. The chimeric ErbB heteromultimer adhesins of the present invention are useful as competitive antagonists or agonists of a neuregulin for the treatment of diseases such as various cancers.
    Type: Grant
    Filed: December 22, 2003
    Date of Patent: February 9, 2010
    Assignee: Genentech, Inc.
    Inventors: Vincent Danial Fitzpatrick, Mark Sliwkowski, Richard L. Vandlen
  • Nucleic acid molecules associated with the tocopherol pathway
    Patent number: 7655777
    Abstract: The present invention is in the field of plant biochemistry. More specifically the invention relates to nucleic acid sequences from plant cells, in particular, nucleic acid sequences from maize and soybean associated with the tocopherol synthesis pathway enzymes. The invention encompasses nucleic acid molecules that encode proteins and fragments of proteins. In addition, the invention also encompasses proteins and fragments of proteins so encoded and antibodies capable of binding these proteins or fragments. The invention also relates to methods of using the nucleic acid molecules, proteins and fragments of proteins and antibodies, for example for genome mapping, gene identification and analysis, plant breeding, preparation of constructs for use in plant gene expression and transgenic plants.
    Type: Grant
    Filed: January 11, 2006
    Date of Patent: February 2, 2010
    Assignee: Monsanto Technology LLC
    Inventors: Barkur G. Bhat, Sekhar S. Boddupalli, Ganesh M. Kishore, Jingdong Liu, Shaukat H. Rangwala, Mylavarapu Venkatramesh